# Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

> **NCT04727541** · PHASE2 · TERMINATED · sponsor: **AIO-Studien-gGmbH** · enrollment: 3 (actual)

## Conditions studied

- Biliary Tract Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** Bintrafusp alfa

## Key facts

- **NCT ID:** NCT04727541
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-08
- **Primary completion:** 2021-10-04
- **Final completion:** 2022-01-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine plus cisplatin, that was discontinued as it was unlikely to meet the primary endpoint of OS, the recruitment for this study was stopped prematurely.
- **Last updated:** 2022-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727541, "Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04727541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*